Zeitschriftenartikel zum Thema „Neuroendocrine transdifferentiation“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Neuroendocrine transdifferentiation" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Sergeant, Camille, Christel Jublanc, Delphine Leclercq, Anne-Laure Boch, Franck Bielle, Gerald Raverot, Adrian F. Daly, Jacqueline Trouillas und Chiara Villa. „Transdifferentiation of Neuroendocrine Cells“. American Journal of Surgical Pathology 41, Nr. 6 (Juni 2017): 849–53. http://dx.doi.org/10.1097/pas.0000000000000803.
Der volle Inhalt der QuelleStone, Louise. „A novel mechanism of neuroendocrine transdifferentiation“. Nature Reviews Urology 15, Nr. 5 (20.03.2018): 263. http://dx.doi.org/10.1038/nrurol.2018.40.
Der volle Inhalt der QuelleCordeiro-Rudnisky, Fernanda, Yue Sun und Rayan Saade. „Prostate Carcinoma With Overlapping Features of Small Cell and Acinar Adenocarcinoma: A Case Report“. American Journal of Clinical Pathology 152, Supplement_1 (11.09.2019): S66—S67. http://dx.doi.org/10.1093/ajcp/aqz113.072.
Der volle Inhalt der QuelleQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Jacklynn V. Egger, Umesh Bhanot, Juan Qiu, Elisa de Stanchina et al. „AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in EGFR-mutant lung adenocarcinoma.“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): e21166-e21166. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21166.
Der volle Inhalt der QuelleYuan, Ta-Chun, Suresh Veeramani und Ming-Fong Lin. „Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells“. Endocrine-Related Cancer 14, Nr. 3 (September 2007): 531–47. http://dx.doi.org/10.1677/erc-07-0061.
Der volle Inhalt der QuelleVon Amsberg, Gunhild, Sergey Dyshlovoy, Jessica Hauschild, Verena Sailer, Sven Perner, Anne Offermann, Lina Merkens et al. „Long-term taxane exposure and transdifferentiation of prostate cancer in vitro.“ Journal of Clinical Oncology 41, Nr. 6_suppl (20.02.2023): 254. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.254.
Der volle Inhalt der QuelleQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah et al. „Abstract 658: AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 658. http://dx.doi.org/10.1158/1538-7445.am2022-658.
Der volle Inhalt der QuelleFrigo, Daniel E., und Donald P. McDonnell. „Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation“. Molecular Cancer Therapeutics 7, Nr. 3 (März 2008): 659–69. http://dx.doi.org/10.1158/1535-7163.mct-07-0480.
Der volle Inhalt der QuellePatel, Girijesh, Sayanika Dutta, Mosharaf Mahmud Syed, Sabarish Ramachandran, Monica Sharma, Venkatesh Rajamanickam, Vadivel Ganapathy et al. „TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p“. Cancers 13, Nr. 19 (07.10.2021): 5020. http://dx.doi.org/10.3390/cancers13195020.
Der volle Inhalt der QuelleTurner, Leo, Andrew Burbanks und Marianna Cerasuolo. „Mathematical insights into neuroendocrine transdifferentiation of human prostate cancer cells“. Nonlinear Analysis: Modelling and Control 26, Nr. 5 (01.09.2021): 884–913. http://dx.doi.org/10.15388/namc.2021.26.24441.
Der volle Inhalt der QuelleCerasuolo, Marianna, Debora Paris, Fabio A. Iannotti, Dominique Melck, Roberta Verde, Enrico Mazzarella, Andrea Motta und Alessia Ligresti. „Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach“. Cancer Research 75, Nr. 15 (11.06.2015): 2975–86. http://dx.doi.org/10.1158/0008-5472.can-14-3830.
Der volle Inhalt der QuelleZhu, Shimiao, Hao Tian, Xiaodan Niu, Jiang Wang, Xing Li, Ning Jiang, Simeng Wen et al. „Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer“. Oncogene 38, Nr. 24 (15.02.2019): 4875–84. http://dx.doi.org/10.1038/s41388-019-0750-5.
Der volle Inhalt der QuelleZamora, Irene, Michael R. Freeman, Ignacio J. Encío und Mirja Rotinen. „Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer“. International Journal of Molecular Sciences 24, Nr. 18 (05.09.2023): 13673. http://dx.doi.org/10.3390/ijms241813673.
Der volle Inhalt der QuelleZhu, Shimiao, Hao Tian, Xiaodan Niu, Jiang Wang, Xing Li, Ning Jiang, Simeng Wen et al. „Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer“. Oncogene 38, Nr. 24 (02.05.2019): 4885. http://dx.doi.org/10.1038/s41388-019-0827-1.
Der volle Inhalt der QuelleWright, Michael E., Ming-Jer Tsai und Ruedi Aebersold. „Androgen Receptor Represses the Neuroendocrine Transdifferentiation Process in Prostate Cancer Cells“. Molecular Endocrinology 17, Nr. 9 (September 2003): 1726–37. http://dx.doi.org/10.1210/me.2003-0031.
Der volle Inhalt der QuelleAzur, Romie Angelo G., Kevin Christian V. Olarte, Weand S. Ybañez, Alessandria Maeve M. Ocampo und Pia D. Bagamasbad. „CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer“. PLOS ONE 19, Nr. 5 (13.05.2024): e0300413. http://dx.doi.org/10.1371/journal.pone.0300413.
Der volle Inhalt der QuelleSlabáková, Eva, Zuzana Kahounová, Jiřina Procházková und Karel Souček. „Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs“. Non-Coding RNA 7, Nr. 4 (02.12.2021): 75. http://dx.doi.org/10.3390/ncrna7040075.
Der volle Inhalt der QuelleGopal, Priyanka, und Mohamed Abazeed. „Abstract 5830: A first-of-its-kind model that reconstitutes targeted drug-induced cellular transdifferentiation“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 5830. http://dx.doi.org/10.1158/1538-7445.am2024-5830.
Der volle Inhalt der QuelleMarzioni, Marco, Stefania Saccomanno, Cinzia Candelaresi, Chiara Rychlicki, Laura Agostinelli, Kumar Shanmukhappa, Luciano Trozzi, Irene Pierantonelli, Samuele De Minicis und Antonio Benedetti. „Pancreatic Duodenal Homeobox-1 de novo expression drives cholangiocyte neuroendocrine-like transdifferentiation“. Journal of Hepatology 53, Nr. 4 (Oktober 2010): 663–70. http://dx.doi.org/10.1016/j.jhep.2010.04.022.
Der volle Inhalt der QuelleZelivianski, Stanislav, Michael Verni, Carissa Moore, Dmitriy Kondrikov, Rodney Taylor und Ming-Fong Lin. „Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype“. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1539, Nr. 1-2 (Mai 2001): 28–43. http://dx.doi.org/10.1016/s0167-4889(01)00087-8.
Der volle Inhalt der QuelleLi, Yinan, Nilgun Donmez, Cenk Sahinalp, Ning Xie, Yuwei Wang, Hui Xue, Fan Mo et al. „SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition“. European Urology 71, Nr. 1 (Januar 2017): 68–78. http://dx.doi.org/10.1016/j.eururo.2016.04.028.
Der volle Inhalt der QuelleClermont, Pier-Luc, Xinpei Ci, Hardev Pandha, Yuzhuo Wang und Francesco Crea. „Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines“. International Journal of Endocrine Oncology 6, Nr. 2 (01.09.2019): IJE20. http://dx.doi.org/10.2217/ije-2019-0008.
Der volle Inhalt der QuelleCi, Xinpei, Jun Hao, Xin Dong, Hui Xue, Rebecca Wu, Stephen Yiu Chuen Choi, Anne M. Haegert et al. „Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development“. Cells 9, Nr. 6 (04.06.2020): 1398. http://dx.doi.org/10.3390/cells9061398.
Der volle Inhalt der QuelleOstano, Paola, Maurizia Mello-Grand, Debora Sesia, Ilaria Gregnanin, Caterina Peraldo-Neia, Francesca Guana, Elena Jachetti, Antonella Farsetti und Giovanna Chiorino. „Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma“. International Journal of Molecular Sciences 21, Nr. 3 (06.02.2020): 1078. http://dx.doi.org/10.3390/ijms21031078.
Der volle Inhalt der QuelleFernandes, Rayzel C., John Toubia, Scott Townley, Adrienne R. Hanson, B. Kate Dredge, Katherine A. Pillman, Andrew G. Bert et al. „Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer“. Cell Reports 34, Nr. 1 (Januar 2021): 108585. http://dx.doi.org/10.1016/j.celrep.2020.108585.
Der volle Inhalt der QuelleYao, Erica, Chuwen Lin, Qingzhe Wu, Kuan Zhang, Hai Song und Pao-Tien Chuang. „Notch Signaling Controls Transdifferentiation of Pulmonary Neuroendocrine Cells in Response to Lung Injury“. STEM CELLS 36, Nr. 3 (01.12.2017): 377–91. http://dx.doi.org/10.1002/stem.2744.
Der volle Inhalt der QuellePisani, David, Daniel Micallef, Jeanesse Scerri, Alexandra Betts, James Degaetano und Shawn Baldacchino. „Neuroendocrine Transdifferentiation in Cutaneous Melanoma: A Case Report and Review of the Literature“. American Journal of Dermatopathology 45, Nr. 4 (17.02.2023): 264–68. http://dx.doi.org/10.1097/dad.0000000000002377.
Der volle Inhalt der QuelleMoritz, Tom, Simone Venz, Heike Junker, Sarah Kreuz, Reinhard Walther und Uwe Zimmermann. „Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells“. Tumor Biology 37, Nr. 8 (05.02.2016): 10435–46. http://dx.doi.org/10.1007/s13277-016-4925-1.
Der volle Inhalt der QuelleZhu, Shimiao, Zhiqun Shang, Hao Tian, Amilcar Flores-Morales und Yuanjie Niu. „AB007. Neurotensin derived from cancer stroma contributes to castration resistance via promoting neuroendocrine transdifferentiation“. Translational Andrology and Urology 5, S1 (April 2016): AB007. http://dx.doi.org/10.21037/tau.2016.s007.
Der volle Inhalt der QuelleMendieta, Irasema, Maricela Rodríguez-Nieto, Rosa Elvira Nuñez-Anita, Jorge Luis Menchaca-Arredondo, Guadalupe García-Alcocer und Laura Cristina Berumen. „Ultrastructural changes associated to the neuroendocrine transdifferentiation of the lung adenocarcinoma cell line A549“. Acta Histochemica 123, Nr. 8 (Dezember 2021): 151797. http://dx.doi.org/10.1016/j.acthis.2021.151797.
Der volle Inhalt der QuelleOELRICH, FELIX, HEIKE JUNKER, MATTHIAS B. STOPE, HOLGER H. H. ERB, REINHARD WALTHER, SIMONE VENZ und UWE ZIMMERMANN. „Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery“. Anticancer Research 41, Nr. 8 (19.07.2021): 3717–29. http://dx.doi.org/10.21873/anticanres.15163.
Der volle Inhalt der QuelleTurner, Leo, Andrew Burbanks und Marianna Cerasuolo. „PCa dynamics with neuroendocrine differentiation and distributed delay“. Mathematical Biosciences and Engineering 18, Nr. 6 (2021): 8577–602. http://dx.doi.org/10.3934/mbe.2021425.
Der volle Inhalt der QuelleDankert, Jaroslaw Thomas, Marc Wiesehöfer, Elena Dilara Czyrnik, Bernhard B. Singer, Nicola von Ostau und Gunther Wennemuth. „The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells“. PLOS ONE 13, Nr. 7 (12.07.2018): e0200472. http://dx.doi.org/10.1371/journal.pone.0200472.
Der volle Inhalt der QuelleAngelucci, A., P. Muzi, G. Pace, L. Cristiano, A. M. Cimini, M. P. Ceru, C. Vicentini und M. Bologna. „513 NEUROENDOCRINE TRANSDIFFERENTIATION INDUCED BY HDAC INHIBITORS CONFERS RESISTANCE TO ANTIBLASTIC THERAPY IN PROSTATE CARCINOMA“. European Urology Supplements 8, Nr. 4 (März 2009): 249. http://dx.doi.org/10.1016/s1569-9056(09)60509-1.
Der volle Inhalt der QuelleBURCHARDT, TATJANA, MARTIN BURCHARDT, MIN-WEI CHEN, YICHEN CAO, ALEXANDRE DE LA TAILLE, AHMED SHABSIGH, OMAR HAYEK, THAMBI DORAI und RALPH BUTTYAN. „TRANSDIFFERENTIATION OF PROSTATE CANCER CELLS TO A NEUROENDOCRINE CELL PHENOTYPE IN VITRO AND IN VIVO“. Journal of Urology 162, Nr. 5 (November 1999): 1800–1805. http://dx.doi.org/10.1016/s0022-5347(05)68241-9.
Der volle Inhalt der QuelleBraadland, Peder R., Håkon Ramberg, Helene Hartvedt Grytli, Alfonso Urbanucci, Heidi Kristin Nielsen, Ingrid Jenny Guldvik, Andreas Engedal et al. „The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells“. Molecular Cancer Research 17, Nr. 11 (08.08.2019): 2154–68. http://dx.doi.org/10.1158/1541-7786.mcr-18-0605.
Der volle Inhalt der QuelleKim, Soojin, Daksh Thaper, Samir Bidnur, Paul Toren, Shusuke Akamatsu, Jennifer L. Bishop, Colin Colins, Sepideh Vahid und Amina Zoubeidi. „PEG10 is associated with treatment-induced neuroendocrine prostate cancer“. Journal of Molecular Endocrinology 63, Nr. 1 (Juli 2019): 39–49. http://dx.doi.org/10.1530/jme-18-0226.
Der volle Inhalt der QuelleInoue, Y., und W. Lockwood. „MA22.02 Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer“. Journal of Thoracic Oncology 13, Nr. 10 (Oktober 2018): S433—S434. http://dx.doi.org/10.1016/j.jtho.2018.08.502.
Der volle Inhalt der QuellePernicová, Zuzana, Eva Slabáková, Radek Fedr, Šárka Šimečková, Josef Jaroš, Tereza Suchánková, Jan Bouchal et al. „The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells“. Molecular Cancer 13, Nr. 1 (2014): 113. http://dx.doi.org/10.1186/1476-4598-13-113.
Der volle Inhalt der QuelleShen, Ruoqian, Thambi Dorai, Matthias Szaboles, Aaron E. Katz, Carl A. Olsson und Ralph Buttyan. „Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium“. Urologic Oncology: Seminars and Original Investigations 3, Nr. 2 (März 1997): 67–75. http://dx.doi.org/10.1016/s1078-1439(97)00039-2.
Der volle Inhalt der QuelleIndo, Sebastián, Octavio Orellana-Serradell, María José Torres, Enrique A. Castellón und Héctor R. Contreras. „Overexpression of REST Represses the Epithelial–Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells“. International Journal of Molecular Sciences 25, Nr. 6 (15.03.2024): 3332. http://dx.doi.org/10.3390/ijms25063332.
Der volle Inhalt der QuelleZhao, Kaihong. „Attractor of a nonlinear hybrid reaction–diffusion model of neuroendocrine transdifferentiation of human prostate cancer cells with time-lags“. AIMS Mathematics 8, Nr. 6 (2023): 14426–48. http://dx.doi.org/10.3934/math.2023737.
Der volle Inhalt der QuelleVlachostergios, Panagiotis J., Athanasios Karathanasis und Vassilios Tzortzis. „Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival“. Genes 13, Nr. 1 (13.01.2022): 135. http://dx.doi.org/10.3390/genes13010135.
Der volle Inhalt der QuelleBishop, Jennifer L., Alastair Davies, Kirsi Ketola und Amina Zoubeidi. „Regulation of tumor cell plasticity by the androgen receptor in prostate cancer“. Endocrine-Related Cancer 22, Nr. 3 (01.05.2015): R165—R182. http://dx.doi.org/10.1530/erc-15-0137.
Der volle Inhalt der QuelleDavidoff, Michail S., Ralf Middendorff, Grigori Enikolopov, Dieter Riethmacher, Adolf F. Holstein und Dieter Müller. „Progenitor cells of the testosterone-producing Leydig cells revealed“. Journal of Cell Biology 167, Nr. 5 (29.11.2004): 935–44. http://dx.doi.org/10.1083/jcb.200409107.
Der volle Inhalt der QuelleSivanandhan, Dhanalakshmi, Sridharan Rajagopal, Chandru Gajendran, Naveen Sadhu, Mohd Zainuddin, Ramachandraiah Gosu und Luca Rastelli. „Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types“. Cancer Research 82, Nr. 23_Supplement_2 (01.12.2022): B029. http://dx.doi.org/10.1158/1538-7445.cancepi22-b029.
Der volle Inhalt der QuelleQiao, Yuanyuan, Chungen Li, Yang Zheng, Xia Jiang, Sarah Nicole Yee, Caleb Cheng, Yi Bao et al. „Abstract 2898: Development of the lipid kinase PIKfyve PROTAC degrader against neuroendocrine prostate cancer“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 2898. http://dx.doi.org/10.1158/1538-7445.am2024-2898.
Der volle Inhalt der QuelleBae, Song Yi, Hannah E. Bergom, Abderrahman Day, Joseph T. Greene, Tanya S. Freedman, Justin H. Hwang und Justin M. Drake. „Abstract B057: ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer“. Cancer Research 83, Nr. 11_Supplement (02.06.2023): B057. http://dx.doi.org/10.1158/1538-7445.prca2023-b057.
Der volle Inhalt der QuelleSyder, A. J., S. M. Karam, J. C. Mills, J. E. Ippolito, H. R. Ansari, V. Farook und J. I. Gordon. „A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype“. Proceedings of the National Academy of Sciences 101, Nr. 13 (30.03.2004): 4471–76. http://dx.doi.org/10.1073/pnas.0307983101.
Der volle Inhalt der QuelleAngelucci, Adriano, Paola Muzi, Loredana Cristiano, Danilo Millimaggi, AnnaMaria Cimini, Vincenza Dolo, Roberto Miano, Carlo Vicentini, Maria Paola Cerù und Mauro Bologna. „Neuroendocrine transdifferentiation induced by VPA is mediated by PPARγ activation and confers resistance to antiblastic therapy in prostate carcinoma“. Prostate 68, Nr. 6 (01.05.2008): 588–98. http://dx.doi.org/10.1002/pros.20708.
Der volle Inhalt der Quelle